This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cytokinetics Drug Fails Trial

Cytokinetics (CYTK - Get Report) said its experimental head-and-neck cancer drug ispinesib failed a clinical trial in which it was meant to reduce or eliminate tumors.

The two-stage trial, involving 20 patients with squamous-cell carcinoma of the head and neck, was designed to study the drug's safety and effectiveness in patients who saw at least a partial reduction in tumor size after infusions of ispinesib.

No patients saw their tumors shrink during the treatment stage of the trial, however, so no participants could advance to the second stage, the company reported. The best overall response was stabilization of the disease in five of the 19 patients evaluated.

Ispinesib belongs to a class of cancer drugs known as KSP inhibitors, which work by targeting a protein that causes tumor cells to multiply. The trial was conducted in conjunction with drug giant GlaxoSmithKline (GSK - Get Report) and the National Cancer Institute.

Cytokinetics shares were losing 22 cents, or 3.5%, to $6.13.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
CYTK $7.34 -0.81%
GSK $42.80 2.60%
AAPL $122.85 -0.43%
FB $95.06 -0.24%
GOOG $627.67 -0.05%


Chart of I:DJI
DOW 17,646.13 +15.86 0.09%
S&P 500 2,096.42 +3.17 0.15%
NASDAQ 5,103.2360 +14.03 0.28%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs